David R. Helton
Chief Scientific Officer
Dr. David R. Helton, holds more than 50 patents from his 40+ years in pharmaceutical research and development. Before joining the team at Defender, Dr. Helton served as the Head of Medical Affairs at Quintiles and the Executive Director of Research at NeoTherapeutics (now Spectum Pharmaceuticals). He founded two companies in the industry: Cenomed BioSciences (acquired by Celgene) and Epiomed Therapeutics (acquired by Repurposed Therapeutics).
Dr. Helton holds a BA in psychology from Wright State University and a PhD in pharmacology from Purdue University.
